1818 Market Street, Suite 2350, Suite 2350
68 articles with Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the following virtual healthcare conference: Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020 at 1:10 p.m. EST / 6:10 p.m. GMT . Daniel Swisher , president and chief operating officer, w
Data at ASH 2020 Annual Meeting Highlights Jazz Pharmaceuticals' Commitment to Advancing Hematology/Oncology Research
18 abstracts spanning Jazz's hematology/oncology therapeutic area to be presented Three abstracts selected for oral presentation, including long-term results from a Phase 3 study of Vyxeos in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia
Jazz Gains Exclusive Global Rights to FAAH Inhibitor PF-04457845 for the Potential Treatment of PTSD Strategically Expands Jazz's Mid-Stage Neuroscience Pipeline into a New Disease Area and Further Optimizes SpringWorks' Strategic Focus on Targeted Oncology Jazz to Make Upfront Payment of $35 Million to SpringWorks with Potential Milestone Payments of Up to $375 Million
10/26/2020It was another busy week for clinical trial updates and news. Here’s a look.
10/12/2020It was a moderately busy week for clinical trial news. Here’s a look.
Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Adult Patients with Idiopathic Hypersomnia
Clinically meaningful and highly statistically significant results for primary and both key secondary endpoints U.S. Food and Drug Administration grants Fast Track designation to Xywav for idiopathic hypersomnia, a serious sleep disorder with no approved treatment options
Program aims to empower patients and their loved ones living with secondary acute myeloid leukemia or myelodysplastic syndromes through powerful tools and real stories [17-September-2020] DUBLIN , Sept. 17, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the launch of Find the Right Fit ( FindTheRightFit-sAML.com ), a U.S. patient educatio
Jazz Pharmaceuticals is proud to support the American Heart Association's sleep health educational content Research demonstrates that disrupted sleep and sleep disorders are associated with a higher risk of cardiovascular and cardiometabolic diseases, including obesity, diabetes, heart attack, stroke and coronary artery disease [15-September-2020] DUBLIN , Se
Jazz Pharmaceuticals Announces New Research Collaboration with Redx Pharma to Discover and Develop Two Targeted Cancer Therapies
Research Collaboration on Two Targeted Oncology Programs in the Ras/Raf/MAP Kinase Pathway Redx to Receive $10 Million Upfront and $10 Million in Year 2 with up to $400 Million in Further Milestone Payments Plus Tiered Royalties on any Future Net Product Sales
Jazz Pharmaceuticals plc announced that the company will webcast its corporate presentations at the following virtual investor conferences:
8/31/2020As August wraps up, there were still clinical trial announcements, although fewer than earlier this summer. Here’s a look.
Jazz Pharmaceuticals to Present New Data on Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Sunosi® (solriamfetol) at Virtual SLEEP 2020
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 10 abstracts will be presented at Virtual SLEEP 2020, the 34 th annual meeting of the Associated Professional Sleep Societies (APSS) from August 28-30
Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy
Xywav is the first FDA approved new treatment option indicated for both cataplexy and excessive daytime sleepiness in people living with narcolepsy in more than 15 years Xywav contains 92 percent less sodium per nightly dose than sodium oxybate, a current standard of care for this patient population as designated by the American Academy of Sleep Medicine Guidelines Narcolepsy is a chronic sleep disorder and is associated with an increased prevalence of certain comorbid condit
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 second quarter financial results on Tuesday, August 4, 2020, after the close of the financial markets
National Comprehensive Cancer Network® adds Zepzelca™ (lurbinectedin) to Clinical Practice Guidelines in Oncology
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Zepzelca™ (lurbinectedin) was added by the National Comprehensive Cancer Network (NCCN®) to the Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for small cell lung cancer (SCLC) on July 7, 2020.
Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelca™ (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer
Approval represents an important advance for adult patients whose metastatic SCLC has progressed on or after platinum-based chemotherapy
Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 2.000% Exchangeable Senior Notes due 2026
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced the pricing of $850 million aggregate principal amount of 2.000% exchangeable senior notes due 2026 in a private offering (the "offering") by Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), to qualified institutional buyers pursuant to Ru
Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2026
Jazz Pharmaceuticals plc announced that Jazz Investments I Limited, its wholly-owned subsidiary, intends to offer, subject to market conditions and other factors, $850 million aggregate principal amount of exchangeable senior notes due 2026 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentations at the following virtual investor conferences:
Jazz Pharmaceuticals to Showcase New Data From its Growing Oncology Portfolio at Virtual ASCO and EHA 2020 Meetings
Findings advance research across multiple therapeutic areas for adult and pediatric patients with rare or complex diseases